The present disclosure relates, according to some embodiments, to methods and systems for purifying proteins having a reduced oxalic acid content from aquatic species and compositions thereof.

The present disclosure relates, according to some embodiments, to methods and systems for purifying proteins having a reduced oxalic acid content from aquatic species and compositions thereof.

To provide a new compound with pores finely tunable in size so as to take up a specific element and release the specific element taken up in the pores as necessary, a synthesis method of the new compound, and a separation and recovery agent. The new compound represented by the following molecular formula:

(NH.sub.4)[Ln(C.sub.2O.sub.4).sub.2(H.sub.2O)]

wherein Ln represents a lanthanide selected from Sm, Eu, Tb, Dy, Ho, Er, Tm, Yb, and Lu.

To provide a new compound with pores finely tunable in size so as to take up a specific element and release the specific element taken up in the pores as necessary, a synthesis method of the new compound, and a separation and recovery agent. The new compound represented by the following molecular formula:

(NH.sub.4)[Ln(C.sub.2O.sub.4).sub.2(H.sub.2O)]

wherein Ln represents a lanthanide selected from Sm, Eu, Tb, Dy, Ho, Er, Tm, Yb, and Lu.

Salts and crystalline forms of (R)-4-((2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1′-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4′-piperidine]-3(2H,4H,7H)-yl)-1-phenylethyl)amino)butanoic acid (formula (1)) show excellent physicochemical properties including, for example, hygroscopicity, related substances, chemical stability. The salts and crystalline forms are useful and suitable for pharmaceutical uses such as the preparation of a pharmaceutical composition containing the same as an active ingredient.

Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of formula (I), pharmaceutical compositions comprising the same, and methods of treating, preventing, and managing various disorders using the compositions provided herein.

The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.

The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.

Provided are crystal forms of compounds represented by formula(II)-formula (VIII) and formula (I)-formula (VIII-1), a preparation method therefor and an application of the compounds and crystal forms in the preparation of a drug for treating a related disease.

##STR00001##

The present invention relates to solriamfetol or novel salts thereof and its process for preparation. More particularly the present invention relates to solriamfetol dibenzoyl-D-tartaric acid salt or solriamfetol di-p-toluoyl-D-tartaric acid salt and their process for preparation. Further the present invention relates to use of solriamfetol dibenzoyl-D-tartaric acid salt or solriamfetol di-p-toluoyl-D-tartaric acid salt for the preparation of solriamfetol hydrochloride.